Motesanib
Neoplastic Syndrome
Eastern Cooperative Oncology GroupSmall moleculePhase 2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Neoplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM University of California, San Francisco | Phase 2/3 | BB |
Irinotecan University of California, San Francisco | Phase 2/3 | BB |
Octreotide Pamoate Eastern Cooperative Oncology Group | Phase 2 | B |
Thalidomide Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Eloxatin University of California, San Francisco | Phase 2/3 | B |
Same molecule, other indications
Motesanib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →